Analysts Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Target Price at $6.25

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $6.25.

A number of equities analysts recently issued reports on the company. Wall Street Zen lowered Xeris Biopharma from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Oppenheimer upped their price objective on Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a report on Friday, May 9th.

Insider Buying and Selling at Xeris Biopharma

In other news, insider Kevin Mcculloch acquired 25,000 shares of Xeris Biopharma stock in a transaction that occurred on Friday, June 13th. The stock was purchased at an average price of $4.38 per share, for a total transaction of $109,500.00. Following the completion of the transaction, the insider directly owned 1,708,585 shares in the company, valued at approximately $7,483,602.30. This trade represents a 1.48% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 6.47% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. NewEdge Advisors LLC purchased a new stake in Xeris Biopharma in the 4th quarter worth approximately $34,000. Apella Capital LLC purchased a new stake in Xeris Biopharma in the 1st quarter worth approximately $55,000. Xponance Inc. acquired a new position in shares of Xeris Biopharma during the 1st quarter valued at $57,000. FORA Capital LLC purchased a new stake in Xeris Biopharma during the 1st quarter worth $60,000. Finally, FNY Investment Advisers LLC purchased a new stake in Xeris Biopharma during the 1st quarter worth $63,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Price Performance

Shares of XERS traded down $0.17 during mid-day trading on Wednesday, reaching $5.01. 620,511 shares of the company's stock traded hands, compared to its average volume of 2,438,351. Xeris Biopharma has a 12 month low of $2.10 and a 12 month high of $6.07. The stock has a market cap of $782.71 million, a P/E ratio of -16.75 and a beta of 0.66. The stock's 50-day moving average is $4.82 and its two-hundred day moving average is $4.41.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The company had revenue of $57.80 million for the quarter, compared to analysts' expectations of $57.61 million. Research analysts predict that Xeris Biopharma will post -0.41 earnings per share for the current year.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.